Imitrex (Sumitriptan) for the treatment of benign headaches:
 

Overview:  The purpose of this study is to determine the efficacy and side effects of sumitriptan (Imitrex) when used as a first line treatment for benign, undifferentiated headaches in ED patients.
 

Primary Endpoints: Patient pain as assessed by VAS

Eligible Patients: Patients between 18 and 40 years of age presenting with headaches that the physician believes to be of benign etiology. Patients are ineligible if they are pregnant or nursing, have a history of liver, kidney, or heart disease, or if they smoke in excess of a pack a day.
 

Study Design: Prospective observational trial
 

Anticipated Benefits: Headache relief, medication is provided free of charge.
 

Potential Risks: Coronary artery spasm and chest pain occur very rarely.
 

Research Associate’s Role: The RA is responsible for identifying, enrolling, and collecting data from eligible patients for this study. RA's must have the PMP physician in charge of the patient verify the inclusion and exclusion criteria prior to enrollment.
 

Physician’s Role: If patient is willing to participate in the study, the RA will ask you make a final determination on the patient’s eligibility. There are a number of disqualifying criteria for the study that you will be asked to review before ordering Imitrex for your patient. If you decide that the patient is still eligible, place an order for Imitrex (study) and the RA will complete the data collection on the study.
 

Location of Study Packets: Team Center A, in a box above the attending physician's computer.